# Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies

> **NCT01611623** · PHASE1 · COMPLETED · sponsor: **Esanex Inc.** · enrollment: 9 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** SNX-5422

## Key facts

- **NCT ID:** NCT01611623
- **Lead sponsor:** Esanex Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2012-11
- **Final completion:** 2013-03
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2013-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01611623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01611623, "Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01611623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*